Latest Insider Transactions at Horizon Therapeutics Public LTD CO (HZNP)
This section provides a real-time view of insider transactions for Horizon Therapeutics Public LTD CO (HZNP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Horizon Therapeutics Public Ltd Co to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Horizon Therapeutics Public Ltd Co's insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 06
2023
|
Michael G Grey Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
58,031
-100.0%
|
$6,731,596
$116.5 P/Share
|
Oct 06
2023
|
Michael G Grey Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
39,361
-100.0%
|
$4,565,876
$116.5 P/Share
|
Oct 06
2023
|
Pascale Witz Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
20,279
-100.0%
|
$2,352,364
$116.5 P/Share
|
Oct 06
2023
|
Pascale Witz Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
25,672
-100.0%
|
$2,977,952
$116.5 P/Share
|
Oct 06
2023
|
Susan Mahony Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
9,306
-100.0%
|
$1,079,496
$116.5 P/Share
|
Oct 06
2023
|
Susan Mahony Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,345
-100.0%
|
$1,084,020
$116.5 P/Share
|
Oct 06
2023
|
Thomas Watkins Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
65,953
-100.0%
|
$7,650,548
$116.5 P/Share
|
Oct 06
2023
|
Thomas Watkins Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
110,447
-100.0%
|
$12,811,852
$116.5 P/Share
|
Oct 06
2023
|
Jeff Himawan Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
44,482
-100.0%
|
$5,159,912
$116.5 P/Share
|
Oct 06
2023
|
Jeff Himawan Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
44,546
-100.0%
|
$5,167,336
$116.5 P/Share
|
Oct 06
2023
|
William F Daniel Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
47,670
-100.0%
|
$5,529,720
$116.5 P/Share
|
Oct 06
2023
|
William F Daniel Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
31,915
-100.0%
|
$3,702,140
$116.5 P/Share
|
Oct 06
2023
|
Gino Santini Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
18,655
-100.0%
|
$2,163,980
$116.5 P/Share
|
Oct 06
2023
|
Gino Santini Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
100,959
-100.0%
|
$11,711,244
$116.5 P/Share
|
Oct 06
2023
|
James Samuel Shannon Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
23,638
-100.0%
|
$2,742,008
$116.5 P/Share
|
Oct 06
2023
|
James Samuel Shannon Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
33,156
-100.0%
|
$3,846,096
$116.5 P/Share
|
Oct 06
2023
|
Patrick Mc Ilvenny Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,874
-100.0%
|
$797,384
$116.5 P/Share
|
Oct 06
2023
|
Elizabeth H.Z. Thompson EVP, Research & Development |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,575
-100.0%
|
$1,690,700
$116.5 P/Share
|
Oct 06
2023
|
Andy Pasternak EVP, Chief Strategy Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
56,338
-100.0%
|
$6,535,208
$116.5 P/Share
|
Oct 06
2023
|
Timothy P Walbert Chairman, President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
257,974
-100.0%
|
$29,924,984
$116.5 P/Share
|
Oct 06
2023
|
Timothy P Walbert Chairman, President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
616,772
-100.0%
|
$71,545,552
$116.5 P/Share
|
Oct 06
2023
|
Aaron Cox EVP, Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
556
-100.0%
|
$64,496
$116.5 P/Share
|
Oct 06
2023
|
Sean M. Clayton EVP, General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
745
-100.0%
|
$86,420
$116.5 P/Share
|
Oct 06
2023
|
Sean M. Clayton EVP, General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,655
-100.0%
|
$887,980
$116.5 P/Share
|
Oct 06
2023
|
Michael A. Des Jardin EVP, Technical Operations |
SELL
Sale (or disposition) back to the issuer
|
Direct |
126,838
-100.0%
|
$14,713,208
$116.5 P/Share
|
Oct 06
2023
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
232,104
-100.0%
|
$26,924,064
$116.5 P/Share
|
Oct 06
2023
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,655
-100.0%
|
$307,980
$116.5 P/Share
|
Oct 02
2023
|
Gino Santini Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,092
+18.61%
|
$346,380
$15.23 P/Share
|
Sep 29
2023
|
Thomas Watkins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
81,323
+23.72%
|
$1,138,522
$14.04 P/Share
|
Sep 29
2023
|
James Samuel Shannon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,850
+26.33%
|
$142,200
$12.19 P/Share
|
Sep 28
2023
|
Michael G Grey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+33.69%
|
$300,000
$15.96 P/Share
|
Sep 26
2023
|
Jeff Himawan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
32,161
+41.93%
|
$418,093
$13.87 P/Share
|
Sep 22
2023
|
Gino Santini Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+20.44%
|
$300,000
$15.96 P/Share
|
Sep 06
2023
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Bona fide gift
|
Indirect |
2,165
-2.61%
|
-
|
May 09
2023
|
Jeff Himawan Director |
BUY
Bona fide gift
|
Indirect |
7,873
+50.0%
|
-
|
May 09
2023
|
Jeff Himawan Director |
SELL
Bona fide gift
|
Direct |
7,873
-78.78%
|
-
|
Apr 28
2023
|
Gino Santini Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,913
+6.33%
|
-
|
Apr 28
2023
|
Thomas Watkins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,913
+11.84%
|
-
|
Apr 28
2023
|
Pascale Witz Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,879
-10.32%
|
$208,569
$111.16 P/Share
|
Apr 28
2023
|
Pascale Witz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,913
+17.69%
|
-
|
Apr 28
2023
|
Susan Mahony Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,879
-48.02%
|
$208,569
$111.16 P/Share
|
Apr 28
2023
|
Susan Mahony Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,913
+50.0%
|
-
|
Apr 28
2023
|
James Samuel Shannon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,879
-8.1%
|
$208,569
$111.16 P/Share
|
Apr 28
2023
|
James Samuel Shannon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,913
+14.44%
|
-
|
Apr 28
2023
|
Jeff Himawan Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,879
-15.83%
|
$208,569
$111.16 P/Share
|
Apr 28
2023
|
Jeff Himawan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,913
+24.79%
|
-
|
Apr 28
2023
|
William F Daniel Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,879
-5.56%
|
$208,569
$111.16 P/Share
|
Apr 28
2023
|
William F Daniel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,913
+10.38%
|
-
|
Apr 28
2023
|
Michael G Grey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,913
+16.81%
|
-
|
Mar 13
2023
|
Elizabeth H.Z. Thompson EVP, Research & Development |
SELL
Bona fide gift
|
Direct |
2,000
-12.07%
|
-
|